Who are Stoke Therapeutics, Inc.'s main suppliers?

Stoke Therapeutics, Inc. (STOK) key suppliers include: NWALP-PHOP-PROPERTY-OWNER-LLC, ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., ORANY, ORANY. View the full supplier network at chainsifter.com/chain/STOK.

Who are Stoke Therapeutics, Inc.'s major customers?

Stoke Therapeutics, Inc. (STOK) key customers include: BIOGEN-INTERNATIONAL-GMBH, ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., Myriad Genetics, Inc., Myriad Genetics, Inc. and 2 more. View the full customer network at chainsifter.com/chain/STOK.

What sector is Stoke Therapeutics, Inc. in?

Stoke Therapeutics, Inc. (STOK) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Stoke Therapeutics, Inc. Suppliers, Customers & Supply Chain (STOK)

5Suppliers

7Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Stoke Therapeutics, Inc. (STOK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

14Total relationships

3Distinct source URLs

4High confidence

0.774Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Stoke Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
NWALP-PHOP-PROPERTY-OWNER-LLC	NWALP-PHOP-PROPERTY-OWNER-LLC	92%	On January 21, 2026, Stoke Therapeutics, Inc. (the "Company") entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC
ACAD	ACADIA Pharmaceuticals Inc.	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ACAD	ACADIA Pharmaceuticals Inc.	72%	Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD g…
ORANY	ORANY	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional i…

Stoke Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BIOGEN-INTERNATIONAL-GMBH	BIOGEN-INTERNATIONAL-GMBH	92%	In connection with the closing of this transaction in February 2025, the Company received an upfront payment of $ 165.0 million and is eligible to receive development and commercial milestone payment…
ACAD	ACADIA Pharmaceuticals Inc.	72%	Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ACAD g…
ACAD	ACADIA Pharmaceuticals Inc.	72%	ort is expected to be completed in the third quarter of 2026. Data from the European cohort are not planned for inclusion in the U.S. NDA submission. ADOA Program – STK-002 We are also pursuing treat…
MYGN	Myriad Genetics, Inc.	72%	expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. Risks Related to our Financial Position We have a history o…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from STOK graph: expire by the other party. Any such termination or expiration would adversely affect us financially and could harm ou…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…

Stoke Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
STOK-DEBT	Debt stack $3.4M	90%	Market cache reports total debt of $3.4M.

Stoke Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
STOK-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders.

Stoke Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ATYR	aTyr Pharma, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ACAD	ACADIA Pharmaceuticals Inc.	100.00	1	['customer', 'supplier']
IMNM	Immunome, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
GHRS	GH Research PLC	100.00	2
PSNL	Personalis, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
DNLI	Denali Therapeutics Inc.	100.00	2

Stoke Therapeutics, Inc. Supply Chain